68 results
8-K
EX-99.1
NTBL
Notable Labs Ltd
8 Apr 24
Other Events
12:15pm
at AACR 2024. The ability to derive a high-quality assessment of the response to treatment based on the results of cryopreserved samples is an important
8-K
EX-99.1
NTBL
Notable Labs Ltd
22 Feb 24
Other Events
8:15am
are i) a positive predicted response rate and ii) a per-protocol response assessment of complete remission and overall survival.
The Phase 2 program
DEF 14A
NTBL
Notable Labs Ltd
16 Feb 24
Definitive proxy
9:00am
by the Compensation Committee and the Board, based on quantitative and qualitative criteria.
Beginning for calendar year 2024, an assessment of Dr … . The actual bonus to be paid (if any) will be determined based on the foregoing assessment of Dr. Bock’s achievement of the objectives for the year
PRE 14A
g4zz7t2hj3nj7l1w
5 Feb 24
Preliminary proxy
5:00pm
8-K
EX-99.1
nr1y31838a5
18 Dec 23
Other Events
8:15am
8-K/A
EX-99.2
g2udyymklhc8jr 79h
29 Nov 23
Financial Statements and Exhibits
5:00pm
424B3
b1teb
5 Sep 23
Prospectus supplement
6:02pm
S-4/A
pyiqfa0
30 Jun 23
Registration of securities issued in business combination transactions (amended)
4:38pm
S-4
1aubjv9dv ghxmuwo
11 May 23
Registration of securities issued in business combination transactions
9:09am
6-K
EX-1.1
y5l01k9
11 Feb 22
Current report (foreign)
5:29pm
424B5
w80x17w8y18mxl u3
11 Feb 22
Prospectus supplement for primary offering
5:28pm
6-K
EX-99.2
s287327 gaytmf
15 Nov 21
VBL Therapeutics Reports Third Quarter 2021 Financial Results
7:00am
6-K
d5rtcmac bv3t
16 Aug 21
Current report (foreign)
7:00am